Yasonya / Shutterstock.com
Secondary medical use case trends and research exemptions are just two issues set to be discussed at C5’s 12th Pharma & Biotech Patent Litigation meeting, on February 25–26 in Amsterdam.
The event comes at a significant time for European IP, with political uncertainty and the current state of IP proving a series of challenges for pharmaceutical and biotech companies conducting business in Europe.
Attendees at C5’s 12th Pharma & Biotech Patent Litigation will obtain clarification on a raft of matters, and develop an understanding of their consequential impact on patent litigation strategies.
Key takeaways for the 2020 event include:
- Developing best practice approaches for new Board of Appeal rules at the European Patent Office;
- Determining which research exemptions are available in Europe and the US; and
- Formulating strategies relative to the latest secondary medical use case trends.
A faculty of in-house counsel and regulatory executives will share solutions and practical approaches to the most pressing IP challenges impacting the life sciences industry.
LSIPR readers will receive a 10% discount when registering with this code: D10-630-630CX02 at https://www.c5-online.com/pharmalitigation
For more information on the event, click here.
C5, medical use, biotech, patent litigation, European IP, Board of Appeal, EPO, in-house counsel, life sciences, pharmaceutical industry